Received by email:
File: Q1 Financials FINAL (Dec. 2, 2016) .docx
3D SIGNATURES INC. REPORTS Q1 FINANCIAL RESULTS
WINNIPEG, MB (December 2, 2016) - 3D Signatures Inc. (TSXV: DXD) (the "Company" or "3DS") reported financial results f
--->or the three months ended September 30, 2016. Amounts, unless specified otherwise, are expressed in Canadian dollars a
--->nd in accordance with International Financial Reporting Standards ("IFRS"). Consolidated condensed interim financial s
--->tatements for the three month period ended September 30, 2016 and the management discussion and analysis ("MD&A") are
--->available to be reviewed on SEDAR or the 3DS web site atwww.3dsignatures.com.
Corporate Strategy
3DS envisions itself as a developer of novel assays and a new class of biomarkers that it intends to license to commer
--->cial partners in key markets around the world. The Company will expand the range of applications and markets through o
--->ngoing research and development. 3DS has assembled an accomplished team with successful track records in the biomedica
--->l market and the development of Laboratory Developed Tests and regulatory approval requirements.
3DS has a balanced market entrance strategy, which combines a fast track Laboratory Developed Test ("LTD") development
---> to generate income, with a longer-term strategy to seek in-vitro diagnostic device (IVDD) approval from Health Canada
--->, the Food and Drug Administration ("FDA") and European regulators. In addition to pursuing LDT and IVDD approvals for
---> its tests, the Company is actively engaging major biopharma companies in collaborations geared towards improving thei
--->r drug-screening capabilities and developing companion diagnostics based on 3DS' novel and proprietary platform. Devel
--->opment costs are being offset by grants and partnerships for efficient use of investment.
Selected Interim Financial Information
The Company has not earned revenues as of November 29, 2016.
The following table sets forth selected consolidated financial information for the three months ended September 30, 20
--->16. It has been derived from our consolidated condensed interim financial statements and accompanying notes, in each c
--->ase prepared in accordance with IFRS. Our consolidated condensed interim financial statements have been reviewed by ou
--->r auditors, MNP LLP. The selected financial information set out below may not be indicative of 3DS' future performance
--->.
($ Cdn)
3 Months Ended September 30, 2016
Income Statement Data
Revenue
$0.00
Operating expenses
3,367,898
(Loss) income
(3,367,898)
_________________________________________________
__________________
September 30, 2016
Balance Sheet Data
Cash and cash equivalents
1,839,572
Receivables and Prepaids
1,969,885
Equipment and Intangible assets
817,822
Total assets
4,627,279
Accounts payable and accrued liabilities
Notes Payable................................................................
604,626
64,487
Shareholders' equity
3,958,166
Total liabilities and equity
4,627,279
The Company is also announcing it has retained Terry Bramhall, Clearcut Communications ("Clearcut"), a Vancouver base
--->d investor relations services provider. Under the terms of the agreement, 3DS will pay Clearcut a monthly fee of $2,00
--->0 for investor relations services. The agreement is for a term of six months.
About 3DS
3DS (TSXV: DXD) is a personalized medicine company with a proprietary software platform based on the three-dimensional
---> analysis chromosomal signatures. The technology is well developed and supported by 16 clinical studies on over 1,500
--->patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, the technology can mea
--->sure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designe
--->d to predict the course of disease and to personalize treatment for the individual patient. For more information, visi
--->t the Company's new website at http://www.3dsignatures.com.
For further information, please contact:
Keith B. Cassidy
Chief Financial Officer
403.870.1485
keith.cassidy@3dsignatures.com
Forward-Looking Information
This news release may contain certain "forward-looking statements" and certain "forward-looking information" as define
--->d under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by
---> the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe"
--->, "continue", "plans" or similar terminology. Forward-looking statements and information are subject to various known
--->and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that m
--->ay cause the Company's actual results, performance or achievements to be materially different from those expressed or
--->implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here
--->in. The Company undertakes no obligation to update forward-looking information except as required by applicable law. S
--->uch forward- looking information represents management's best judgment based on information currently available. No fo
--->rward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advi
--->sed not to place undue reliance on forward-looking statements or information.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the T
--->SX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
File: Q1 Financials FINAL (Dec. 2, 2016) .pdf
3D SIGNATURES INC. REPORTS Q1 FINANCIAL RESULTS
WINNIPEG, MB (December 2, 2016) - 3D Signatures Inc. (TSXV: DXD) (the "Company" or
"3DS") reported financial results for the three months ended September 30, 2016. Amounts,
unless specified otherwise, are expressed in Canadian dollars and in accordance with
International Financial Reporting Standards ("IFRS"). Consolidated condensed interim
financial statements for the three month period ended September 30, 2016 and the
management discussion and analysis ("MD&A") are available to be reviewed on SEDAR or
the 3DS web site atwww.3dsignatures.com.
Corporate Strategy
3DS envisions itself as a developer of novel assays and a new class of biomarkers that it
intends to license to commercial partners in key markets around the world. The Company
will expand the range of applications and markets through ongoing research and
development. 3DS has assembled an accomplished team with successful track records in
the biomedical market and the development of Laboratory Developed Tests and regulatory
approval requirements.
3DS has a balanced market entrance strategy, which combines a fast track Laboratory
Developed Test ("LTD") development to generate income, with a longer-term strategy to
seek in-vitro diagnostic device (IVDD) approval from Health Canada, the Food and Drug
Administration ("FDA") and European regulators. In addition to pursuing LDT and IVDD
approvals for its tests, the Company is actively engaging major biopharma companies in
collaborations geared towards improving their drug-screening capabilities and developing
companion diagnostics based on 3DS' novel and proprietary platform. Development costs
are being offset by grants and partnerships for efficient use of investment.
Selected Interim Financial Information
The Company has not earned revenues as of November 29, 2016.
The following table sets forth selected consolidated financial information for the three
months ended September 30, 2016. It has been derived from our consolidated
condensed interim financial statements and accompanying notes, in each case
prepared in accordance with IFRS. Our consolidated condensed interim financial
statements have been reviewed by our auditors, MNP LLP. The selected financial
information set out below may not be indicative of 3DS' future performance.
3 Months Ende
--->d
September 30,
--->2016
($ Cdn)
Income Statement Data
Revenue ...................................................................................... $0.00
Operating expenses .................................................................... 3,367,898
(Loss) income .............................................................................. (3,367,898)
_________________________________________________ __________________
September 30,
--->2016
Balance Sheet Data
Cash and cash equivalents ......................................................... 1,839,572
Receivables and Prepaids ........................................................... 1,969,885
Equipment and Intangible assets ................................................ 817,822
Total assets ................................................................................ 4,627,279
Accounts payable and accrued liabilities ..................................... 604,626
Notes Payable................................................................ 64,487
Shareholders' equity .................................................................... 3,958,166
Total liabilities and equity......................................................... 4,627,279
The Company is also announcing it has retained Terry Bramhall, Clearcut Communications
("Clearcut"), a Vancouver based investor relations services provider. Under the terms of the
agreement, 3DS will pay Clearcut a monthly fee of $2,000 for investor relations services. The
agreement is for a term of six months.
About 3DS
3DS (TSXV: DXD) is a personalized medicine company with a proprietary software platform based
on the three-dimensional analysis chromosomal signatures. The technology is well developed and
supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's
disease. Depending on the desired application, the technology can measure the stage of disease,
rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to
predict the course of disease and to personalize treatment for the individual patient. For more
information, visit the Company's new website at http://www.3dsignatures.com.
For further information, please contact:
Keith B. Cassidy
Chief Financial Officer
403.870.1485
keith.cassidy@3dsignatures.com
---> 2
Forward-Looking Information
This news release may contain certain "forward-looking statements" and certain "forward-looking
information" as defined under applicable Canadian securities laws. Forward-looking statements
and information can generally be identified by the use of forward-looking terminology such as
"may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar
terminology. Forward-looking statements and information are subject to various known and
unknown risks and uncertainties, many of which are beyond the ability of the Company to control
or predict, that may cause the Company's actual results, performance or achievements to be
materially different from those expressed or implied thereby, and are developed based on
assumptions about such risks, uncertainties and other factors set out herein. The Company
undertakes no obligation to update forward-looking information except as required by applicable
law. Such forward- looking information represents management's best judgment based on
information currently available. No forward-looking statement can be guaranteed and actual future
results may vary materially. Accordingly, readers are advised not to place undue reliance on
forward-looking statements or information.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in
the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of
this release.
3
© 2024 Canjex Publishing Ltd. All rights reserved.